Cogstate Ltd · ASX:CGS
Cogstate — Shareholder Meeting (October 2010)
14 slides from Cogstate's shareholder meeting presentation, Oct 21, 2010
Slide 1: Annual General Meeting
For personal use only Annual General Meeting Thursday 21 October 2010 1
Slide 2: CogState provides technology solutions for assessment of thinking
CogState provides… For personal use only Technology solutions for the assessment of thinking in humans 2
Slide 3: Business Segments
Business Segments For personal use only • Clinical drug trials – Customers are pharma / biotech companies – Quantify the effects of drugs on human subjects in clinical trials • Sport – Customers are athletes, parents, schools, doctors, sports teams or sporting associations – Quick and efficient web
Slide 4: Financial results – June 2010
Financial results – 30 June 2010 For personal use only • 2nd consecutive profit result, with Net Profit After Tax A$1.6 million • Operating profit A$0.5 million impacted by development costs : – A new product (NTB) that will deliver sales growth in Alzheimer’s disease studies – Resources devoted to
Slide 5: Sales growth impacted by A$ strength
Sales growth impacted by A$ strength For personal use only • Sales contracts and invoices denominated in US$ • Measured in US$, sales grew by 35% in 2010 • Expect even greater currency impact for FY2011 5
Slide 6: Sales contracts – June 2010
Sales contracts – 30 June 2010 For personal use only • 23% growth in sales contracts, measured in US$ 6
Slide 7: Commercial opportunity
Commercial opportunity For personal use only CogState’s core business has delivered consecutive profit results We know that we have technology that is reliably sensitive to changes in thinking The opportunity is to use that same technology to answer questions about people’s thinking in the broader c
Slide 8: Opportunities in core business - clinical trials
Opportunities in core business - clinical trials For personal use only We’ve added to our product line (NTB) and developed systems to support the use of paper and pencil tests and … we can further enhance our product line, using those same systems to support additional tests and provide a full servi
Slide 9: Sport
Sport For personal use only Axon Sports, a joint venture www.axonsports.com between CogState and Quixote Investment LLC, was launched in the US in August 2010 Partners providing sports product marketing and distribution expertise Total US market estimated at US$150 – US$275 million p.a. Extensive pr
Slide 10: Concussion in sport is a serious issue
Concussion in sport is a serious issue For personal use only 10
Slide 11: Research & Development Activities
Research & Development Activities For personal use only • Early detection of Alzheimer’s disease – Cognitive decline on the CogState memory test predicts a 3 fold increased risk of early AD – Our studies in 50+ year olds have shown 53% with memory decline have excess amyloid on Memory decline PET sc
Slide 12: Research & Development Activities
Research & Development Activities For personal use only • Platforms for large longitudinal studies – 1000’s of study participants living in the community – Can’t use traditional methods of cognitive assessment – Online testing for cost-effective and remote screening to detect those requiring detaile
Slide 13: Conclusions
Conclusions For personal use only • Significant upside for CogState as we seek to expand our core business – Focus on Alzheimer’s disease – Use technological data integrity tools to increase use in other disease indications – Look to build alliances in pharma industry (as we did in the Sport market)
Slide 14: First half forecast – FY2011
First half forecast – FY2011 For personal use only • All revenues are expected to come from clinical trials – Axon Sports will be equity accounted below the Operating Profit line – Screening will not generate any significant revenue in H1 • H1 sales contracts are expected to be approx equal to the p